Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited is set to issue new shares and options following approval at their upcoming General Meeting. The company is making strides in developing Xanamem, a novel therapy targeting neurological diseases like Alzheimer’s and depression by controlling brain cortisol levels. Early clinical trials have shown promising results, generating interest among investors in the biotech sector.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
